IL-17A targeting biobetter (Abeome)

N/A

Report date: 2025/01/26 18:48:22

Base Information

Drug NameIL-17A targeting biobetter (Abeome)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionInterleukin 17A modulators

TargetsInterleukin 17A

Therapy Area/IndicationsInflammationPsoriasisArthritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbeome Corp

China Registration ClassN/A

Develop Information

Active CompaniesAbeome Corp

Inactive CompaniesN/A

Active IndicationsPsoriasisArthritis

Inactive IndicationsInflammation

Other Information

ATC CodeN/A